Company profile
Cogent Biosciences, Inc.
NASDAQ: COGT · Healthcare · Biotechnology
#656 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
48DFH 48DQ 48GM 34SS 70
v0.1 · 65/100 weight · provisional
↑ market scale, Altman-Z · ↓ growth stability, operating margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$328.9M
Employees
258
as of 2026-08-06
Market cap
$7.2B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$7.9M$7.9M2020
Net income-$328.9M-$328.9M2025
Operating income-$333.4M-$333.4M2025
Total assets$937.6M$937.6M2025
Liabilities$301.2M$301.2M2025
Equity$636.4M$636.4M2025
Revenue trend
FY2018 – FY2020 · USD
FY18
FY18
FY18
FY19
FY19
FY19
FY19
FY20
Revenue by segment
Filed disclosures · FY2019
By product
Preclinical Research And Clinical Development100%
By geography
Not disclosed.
The read
What is Cogent Biosciences, Inc.’s revenue?
Cogent Biosciences, Inc. booked $7.9M in FY2020 revenue, contracting 65% year over year — slower than 85% of Healthcare companies we track, at a -4179.1% net margin.
Peers · Healthcare
Solid Biosciences Inc.41DNextleaf Solutions Ltd.57CCoya Therapeutics, Inc.48DAclaris Therapeutics, Inc.47DPulmatrix, Inc.46DCrinetics Pharmaceuticals, Inc.53DNeighbors
Middlesex →Key facts
CEOAndrew R. Robbins
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: COGT
Employees258
IPO date2018-03-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.